These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8288039)

  • 41. [Effect of insulin on aldose reductase activity in the lens of rats with streptozotocin-induced diabetes].
    Nishigami T
    Nippon Ganka Gakkai Zasshi; 1990 Feb; 94(2):128-34. PubMed ID: 2114733
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New approaches for treatment in diabetes: aldose reductase inhibitors.
    Hotta N
    Biomed Pharmacother; 1995; 49(5):232-43. PubMed ID: 7579002
    [No Abstract]   [Full Text] [Related]  

  • 43. Aldose reductase expression as a risk factor for cataract.
    Snow A; Shieh B; Chang KC; Pal A; Lenhart P; Ammar D; Ruzycki P; Palla S; Reddy GB; Petrash JM
    Chem Biol Interact; 2015 Jun; 234():247-53. PubMed ID: 25541468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does aldose reductase have a role in the development of the ocular complications of diabetes?
    Lightman S
    Eye (Lond); 1993; 7 ( Pt 2)():238-41. PubMed ID: 7607342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sorbinil, an Aldose Reductase Inhibitor, in Fighting Against Diabetic Complications.
    Huang Q; Liu Q; Ouyang D
    Med Chem; 2019; 15(1):3-7. PubMed ID: 29792152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications.
    Van Zandt MC; Sibley EO; McCann EE; Combs KJ; Flam B; Sawicki DR; Sabetta A; Carrington A; Sredy J; Howard E; Mitschler A; Podjarny AD
    Bioorg Med Chem; 2004 Nov; 12(21):5661-75. PubMed ID: 15465344
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulation of lens aldose reductase activity by nitric oxide.
    Srivastava S; Tammali R; Chandra D; Greer DA; Ramana KV; Bhatnagar A; Srivastava SK
    Exp Eye Res; 2005 Dec; 81(6):664-72. PubMed ID: 15967436
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Diabetic neuropathies. Metabolism of sorbitol in sciatic nerve tissue in streptozotocin diabetes].
    Kryvko IuIa; Kozyts'kyĭ ZIa; Serhiienko OO; Kuchmerovs'ka TM; Velykyĭ MM
    Ukr Biokhim Zh (1999); 2001; 73(5):69-74. PubMed ID: 12035507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Treatment of chronic microvascular complications of diabetes mellitus with aldose reductase inhibitors].
    Wajchenberg BL
    Rev Assoc Med Bras (1992); 1996; 42(2):63-5. PubMed ID: 9110450
    [No Abstract]   [Full Text] [Related]  

  • 50. Aldose reductase inhibitors and late complications of diabetes.
    Benfield P
    Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of aldose reductase in the development of diabetic complications.
    Kador PF
    Med Res Rev; 1988; 8(3):325-52. PubMed ID: 3136278
    [No Abstract]   [Full Text] [Related]  

  • 52. Nitric oxide prevents aldose reductase activation and sorbitol accumulation during diabetes.
    Chandra D; Jackson EB; Ramana KV; Kelley R; Srivastava SK; Bhatnagar A
    Diabetes; 2002 Oct; 51(10):3095-101. PubMed ID: 12351453
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diabetic retinopathy.
    Barr CC
    J Ky Med Assoc; 1986 Apr; 84(4):155-8. PubMed ID: 2422308
    [No Abstract]   [Full Text] [Related]  

  • 54. Increased white cell aldose reductase mRNA levels in diabetic patients.
    Kicic E; Palmer TN
    Diabetes Res Clin Pract; 1996 Jun; 33(1):31-6. PubMed ID: 8877273
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Jung SH; Lee YS; Shim SH; Lee S; Shin KH; Kim JS; Kim YS; Kang SS
    Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications.
    Obrosova IG
    Antioxid Redox Signal; 2005; 7(11-12):1543-52. PubMed ID: 16356118
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current status of aldose reductase inhibitors.
    Zimmerman BR
    Diabetes Care; 1987; 10(1):123-5. PubMed ID: 3105984
    [No Abstract]   [Full Text] [Related]  

  • 58. The sorbitol pathway. Enzyme localization and content in normal and diabetic nerve and cord.
    Gabbay KH; O'Sullivan JB
    Diabetes; 1968 May; 17(5):239-43. PubMed ID: 4384869
    [No Abstract]   [Full Text] [Related]  

  • 59. The role of protein kinase C in the development of the complications of diabetes.
    Ways DK; Sheetz MJ
    Vitam Horm; 2000; 60():149-93. PubMed ID: 11037624
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Polymorphisms of the aldose reductase gene and susceptibility to diabetic microvascular complications.
    Demaine AG
    Curr Med Chem; 2003 Aug; 10(15):1389-98. PubMed ID: 12871136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.